Introduction {#s1}
============

IgA nephropathy (IgAN) is the most common form of glomerular disease worldwide, with an incidence that ranges from 20% to 40% in patients with primary glomerulonephritis [@pone.0051225-Donadio1]. The relative incidence of IgAN has increased recently, especially in Korea [@pone.0051225-Chang1]. Despite the well-known heterogeneity of the disease and a generally slow course of disease progression, IgAN is a significant contributor to end stage renal disease (ESRD) progression [@pone.0051225-Donadio1], [@pone.0051225-Radford1], [@pone.0051225-Bartosik1]. Indeed, numerous studies have addressed the clinical [@pone.0051225-Radford1]--[@pone.0051225-Xie1] and pathological [@pone.0051225-Radford1], [@pone.0051225-Shi1]--[@pone.0051225-Frimat1] risk factors linked to the risk of progression. These include initial renal impairment [@pone.0051225-Radford1], [@pone.0051225-Beukhof1], [@pone.0051225-Xie1], heavier or prolonged proteinuria [@pone.0051225-Bartosik1]--[@pone.0051225-Alamartine1], [@pone.0051225-Berthoux1], hypertension [@pone.0051225-Alamartine1], [@pone.0051225-Berthoux1], [@pone.0051225-Xie1], and several histological changes [@pone.0051225-Radford1], [@pone.0051225-Alamartine1], [@pone.0051225-Berthoux1], [@pone.0051225-Frimat1]. However, the mortality data are not reported in most IgAN survival studies. Patient death has been considered as one part of a composite outcome [@pone.0051225-Berthoux1], [@pone.0051225-Walsh1], [@pone.0051225-Kim1] or analyzed only descriptively [@pone.0051225-Bjorneklett1]. The mortality rate or its predictors have not been addressed in previous studies. Therefore, according to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for glomerulonephritis (to be published), there is an assumption that IgAN patients had higher mortality than the general population (GP), and that cardiovascular morbidity and mortality increase in these patients, as in others with chronic kidney disease.

IgAN patients are usually diagnosed at a relatively young age, and most have a benign clinical course in our clinical practice. Moreover, these patients are thought to be more likely to receive transplantation because of their relatively younger age even after ESRD progression compared to their diabetic ESRD counterparts. Such clinical experiences suggest a favorable patient outcome in IgAN patients. Therefore, the rate of IgAN progression to patient death needs to be clarified, as do the clinical or pathological risk factors involved. The main purpose of this retrospective observational study was to describe the definitive patient outcome and analysis of their predictive factors, compared with renal outcome and its indicators.

10.1371/journal.pone.0051225.t001

###### Baseline demographic and clinical characteristics.

![](pone.0051225.t001){#pone-0051225-t001-1}

                                                               Death               ESRD                                                        
  ----------------------------------- ------------------ ------------------ ------------------ --------- ------------------ ------------------ ---------
  **At the time of biopsy** (**n**)         1,364              1,276                71                         1,067               277         
  Age (years)                             33(25--45)         32(22--44)         47(36--61)      \<0.001      33(24--44)         36(28--46)       0.001
  Sex (male)                              682(50.0)          632(49.5)           43(60.6)        0.087       513(48.1)          161(58.1)        0.003
  SBP (mmHg)                            120(110--138)      120(110--130)      140(124--150)     \<0.001    120(110--130)      130(120--150)     \<0.001
  Co-morbidity                                                                                                                                 
  Diabetes                                 25(2.0)            22(1.9)             3(5.0)         0.120        18(1.9)             7(2.7)         0.037
  Cancer                                   10(0.8)             4(0.3)            6(10.0)        \<0.001        7(0.7)             3(1.2)         0.448
  Hypertension                            484(38.7)          442(37.2)           42(67.7)       \<0.001      319(32.4)          165(62.3)       \<0.001
  Clinical manifestations                                                                                                                      
  Edema                                   314(24.1)          288(23.2)           26(40.0)        0.004       210(20.3)          104(38.4)       \<0.001
  Gross hematuria                         438(33.2)          417(33.3)           21(31.3)        0.791       370(35.4)           70(25.5)        0.002
  AUA                                     457(35.0)          442(35.6)           15(22.7)        0.034       386(37.3)           71(26.0)       \<0.001
  Laboratory tests                                                                                                                             
  Hemoglobin (g/dL)                    13.3(11.8--14.6)   13.3(11.9--14.6)   11.7(9.4--13.9)    \<0.001   13.5(12.1--14.7)   12.1(10.5--13.9)   \<0.001
  Albumin (g/dL)                        3.9(3.5--4.2)      3.9(3.5--4.2)      3.3(2.7--3.9)     \<0.001    3.9(3.6--4.2)      3.6(3.1--4.0)     \<0.001
  Cholesterol (mg/dL)                   186(158--220)      186(158--219)      209(154--239)      0.125     184(157--216)      203(166--233)     \<0.001
  Creatinine (mg/dL)                   1.10(1.10--1.50)   1.10(0.90--1.40)   1.50(1.20--2.15)   \<0.001   1.10(0.90--1.30)   1.70(1.20--2.40)   \<0.001
  eGFR (mL/min/1.73m^2^)                  67.6(27.6)         68.7(27.4)         48.3(25.4)      \<0.001      73.5(25.2)         45.7(24.9)      \<0.001
  24hour proteinuria (g/day)           1.30(0.56--2.50)   1.22(0.54--2.36)   2.62(1.60--5.44)   \<0.001   1.11(0.50--2.12)   2.11(1.03--3.46)   \<0.001
  **During follow-up** (**n**)               1223               1163                60                          965                258         
  Development of cancer                    47(3.8)            35(3.0)            12(20.0)       \<0.001       30(3.1)            17(6.6)         0.016
  Development of diabetes                  73(6.0)            66(5.7)             7(9.6)         0.084        50(5.2)            23(8.9)         0.037
  Medical treatment (n)                      1050               1009                41                          842                208         
   Antiplatelet agents                    695(64.8)          322(31.3)           6(14.0)         0.017       265(30.9)           63(29.6)        0.740
   Statin                                 146(13.6)          142(13.8)            4(9.3)         0.501       117(13.6)           29(13.6)        1.000
   RAS blockade                           328(30.6)          675(65.6)           20(46.5)        0.014       557(64.9)          137(64.3)        0.873
   Immunosuppressant                      137(12.7)          124(12.0)           13(30.2)        0.002       103(12.0)           34(15.9)        0.137

All continuous variables are shown as mean (SD) for normal distributions, or median (interquartile range) for non-parametric variables. Categorical variables were frequency per observation (N (%)). Baseline characteristics for patients who progressed to the primary outcome were compared with those who did not using χ^2^ test for dichotomous variables, and student t-test for parametric continuous variables.

Abbreviations: ESRD, end stage renal disease; BMI, body mass index; AUA, asymptomatic urinary abnormalities; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; TA, tubular atrophy; RAS, renin-angiotensin system.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

This investigation was approved by the institutional review board in Seoul National University Hospital and was in accordance with the principle of the Helsinki Declaration II (H-1010-055-336). As the study was retrospective in design and did not include any interventions, informed consent was waived.

Study subjects {#s2b}
--------------

From 1979 to 2008, a kidney biopsy registry was constructed using 4,998 kidney needle biopsy cases among patients aged ≥15 years at the Seoul National University Hospital. Allograft biopsy cases were excluded from this cohort. Among the retrospective cohort, a primary diagnosis of IgAN was made in 1,379 patients. Fifteen of these patients who had less than 5 glomeruli in their biopsy specimen had insufficient information for diagnosis and were excluded from this study [@pone.0051225-Kang1], [@pone.0051225-Myllymki1]. The diagnosis was based on immunofluorescence microscopy showing mesangial IgA deposition as the predominant or co-dominant immunoglobulin, and on the lack of clinical or laboratory evidence of systemic lupus erythematosus, Henoch-Schonlein nephrtis, or liver cirrhosis. In case of lupus nephritis, only the patients with clinical suspicion for lupus nephritis were further tested for lupus autoantibodies.

10.1371/journal.pone.0051225.t002

###### Pathologic changes of study population.

![](pone.0051225.t002){#pone-0051225-t002-2}

                                                      Death            ESRD                                                    
  --------------------------- ----------------- ----------------- --------------- ------- ----------------- ------------------ ---------
  Number of glomerulus           64(21--55)        35(22--56)       26(18--43)     0.007     38(23--58)         26(17--40)      \<0.001
  Global sclerosis (%)         14.8(3.7--34.9)   14.3(3.4--34.2)   25(5.6--46.2)   0.020   11.3(2.4--27.2)   37.5(19.2--59.3)   \<0.001
  Segmental sclerosis (%)       6.8(0--14.3)      6.9(0--14.3)     3.3(0--16.7)    0.193    6.1(0--13.0)     11.2(3.4--19.1)    \<0.001
  Crescent (yes)                  268(21.3)         246(20.7)        22(32.8)      0.022      210(21.2)          58(21.8)        0.866
  TA/Interstitial fibrosis                                                         0.004                                        \<0.001
  None                            119(9.6)          114(9.7)          5(7.9)                  106(10.8)          13(5.0)       
  Mild                            517(41.8)         498(42.4)        19(30.2)                 472(48.3)          45(17.2)      
  Moderate                        375(30.3)         358(30.5)        17(27.0)                 291(23.5)          84(32.1)      
  Severe                          228(18.3)         205(17.4)        22(34.9)                 108(11.1)         120(45.8)      
  Interstitial inflammation                                                        0.014                                        \<0.001
  None                            163(13.2)         155(13.2)         7(11.1)                 133(13.6)          30(11.5)      
  Mild                            485(39.1)         467(39.7)        18(26.6)                 447(45.8)          38(14.5)      
  Moderate                        380(30.7)         362(30.8)        18(26.6)                 293(30.0)          87(22.9)      
  Severe                          211(17.0)         191(16.3)        20(31.7)                 104(10.6)         107(40.8)      
  Vascular change                                                                  0.042                                        \<0.001
  None                            769(62.0)         736(62.7)        32(50.0)                 657(67.2)         112(43.1)      
  Hyalinosis                      215(17.4)         199(17.0)        16(25.0)                 148(15.1)          66(25.4)      
  Atherosclerotic change          255(20.6)         239(20.3)        16(25.0)                 173(17.7)          82(31.6)      
  WHO pathologic grade (n)          1077              1027              50                       858               219         
  I                                31(2.9)           31(3.0)          0(0.0)                   29(3.4)            2(0.9)       
  II                              272(25.3)         267(26.0)         5(10.0)                 265(30.9)           7(3.2)       
  III                             464(43.1)         446(43.5)        18(36.0)                 398(46.4)          66(30.1)      
  IV                              191(17.8)         178(17.3)        13(26.0)                 124(14.5)          67(30.6)      
  V                               118(11.0)         104(10.1)        14(11.9)                  42(4.9)           77(35.2)      

All continuous variables are shown as mean (SD) for normal distributions, or median (interquartile range) for non-parametric variables. Categorical variables were frequency per observation (N (%)). Pathological characteristics for patients who progressed to the primary outcome were compared with those who did not using χ^2^ test for dichotomous variables, and student t-test for parametric continuous variables. Abbreviations: ESRD, end stage renal disease; TA, tubular atrophy;

Clinical data {#s2c}
-------------

Baseline demographic and clinical characteristics were obtained from a review of the medical records at the time of biopsy. Demographic and clinical parameters including age, sex, blood pressure, blood chemistry analysis and 24-h urine protein were obtained. Information about co-morbidities was also collected. Hypertension was defined as a reported history of hypertension, a systolic blood pressure (SBP) ≥140 mmHg, or a diastolic blood pressure ≥90 mmHg. Diabetes mellitus was defined as a reported history of diabetes or as the active use of an oral hypoglycemic agent or insulin. Anemia was defined as a hemoglobin level \<13 g/dL for men and \<12 g/dL for women. The estimated glomerular filtration rate (eGFR) was calculated by the modified modification of diet in renal disease equation after measuring serum creatinine. Data on medication were collected if any of the following was started within 6 months of renal biopsy and was prescribed for more than 3 months: renin-angiotensin system blockades, including any kind of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker; any kind of glucocorticoid; statins; and antiplatelet agents such as aspirin or clopidogrel.

![Cumulative renal and patient survival after renal biopsy.\
The primary endpoint was renal (A) and patient survival (B) and composite outcome (C). The numbers of patients remaining at 60, 120, 180, 240, 300, and 360 months of follow-up are shown at the bottom. ESRD, end stage renal disease.](pone.0051225.g001){#pone-0051225-g001}

To evaluate histopathological change, 2 pathologists reviewed the renal biopsy slides. In the glomerular area, the numbers of glomeruli, proportions of global sclerosis, segmental sclerosis, and crescent lesion were calculated. The percentages of glomeruli with these lesions were deduced and categorized. In the tubulointerstitial area, tubular atrophy and interstitial fibrosis, interstitial inflammatory cell infiltration, and vascular change were graded. The histopathological grades were also analyzed using the WHO grading system for IgAN.

Outcome measurement {#s2d}
-------------------

The outcomes were the death from any cause and ESRD progression (permanent hemodialysis, peritoneal dialysis or renal transplantation) after renal biopsy. Data on mortality and cause of death were obtained from the Korean National Statistical Office (KNSO), and ESRD data were collected from the Korea ESRD registry [@pone.0051225-Kim2]. We combined all these data according to the unique identification number held by all Koreans. In addition, the medical records were searched retrospectively to obtain additional information related to the primary outcome and the recent renal function of the patients. It was assumed that patients who had no follow-up with our institution and no follow-up creatinine values, and who did not undergo any renal replacement therapy or a reported death did not meet the primary endpoint at the time the database closed.

![Cumulative renal\
(**A**) **and patient survival** (**B**) **according to the risk stratification.** The primary outcome is patient survival. The numbers of patients remaining at 60, 120, 180, 240, 300, and 360 months of follow-up are shown at the bottom.](pone.0051225.g002){#pone-0051225-g002}

10.1371/journal.pone.0051225.t003

###### Univariate and multivariate time dependent cox regression analyses for patient death and renal death.

![](pone.0051225.t003){#pone-0051225-t003-3}

                                                Univariate analysis   Multivariate analysis                                                                  
  --------------- ---------------------------- --------------------- ----------------------- ----------------- --------- -------- -------- ----------------- ---------
  **ESRD**         eGFR ≥90(mL/min/1.73m^2^)           Ref.                   Ref.                 Ref.                    Ref.     Ref.         Ref.        
                             60--90                   14.403                  4.151            1.990--8.658     \<0.001   5.024    2.395     1.116--5.141      0.025
                             30--60                   48.996                 12.988            6.335--26.627    \<0.001   27.808   7.330     3.496--15.368    \<0.001
                             15--30                   91.860                 40.496           18.998--86.322    \<0.001   35.737   12.828    5.557--29.612    \<0.001
                              \<15                    122.268                84.995           38.673--186.804   \<0.001   69.844   41.724   17.393--100.092   \<0.001
                          Hypertension                57.262                  2.693            2.084--3.481     \<0.001   9.667    1.698     1.216--2.370      0.002
                    Segmental sclerosis ≥20%          38.746                  2.480            1.863--3.301     \<0.001   8.063    1.674     1.173--2.389      0.005
                        Gross hematuria               31.694                  0.435            0.326--0.582     \<0.001   5.753    0.613     0.411--0.914      0.016
                       Albumin \<3.5 g/dL             63.312                  2.741            2.138--3.514     \<0.001   4.416    1.429     1.024--1.993      0.036
  **Death**              Age \<40 years                Ref.                   Ref.                 Ref.                    Ref.     Ref.         Ref.        
                             40--59                   20.440                  3.718            2.104--6.571     \<0.001   4.626    2.229     1.074--4.626      0.031
                              ≥60                     101.088                24.493           13.130--45.691    \<0.001   49.267   15.627    7.253--33.670    \<0.001
                         SBP ≥140 mmHg                28.157                  3.730            2.294--6.065     \<0.001   9.121    2.484     1.376--4.482      0.003
                       Albumin \<3.5 g/dL             39.264                  4.778            2.930--7.794     \<0.001   8.481    2.470     1.344--4.539      0.003
                             Cancer                   28.999                  5.745            3.040--10.855    \<0.001   3.943    2.224     1.010--4.894      0.047
  **Composite**          Age \<40 years                Ref.                   Ref.                 Ref.                    Ref.     Ref.         Ref.        
                             40--59                   16.913                  1.695            1.318--2.180     \<0.001   1.520    0.672     0.358--1.264      0.218
                              ≥60                     60.809                  4.582            3.125--6.718     \<0.001   14.317   5.351     2.244--12.757    \<0.001
                             Cancer                   23.350                  2.760            1.828--4.166     \<0.001   13.545   2.882     1.640--5.064     \<0.001
                   eGFR ≥90 (mL/min/1.73m^2^)          Ref.                   Ref.                 Ref.                    Ref.     Ref.         Ref.        
                             60--90                   15.181                  3.523            1.870--6.639     \<0.001   1.306    1.518     0.742--3.107      0.253
                             30--60                   58.847                 11.161            6.026--20.672    \<0.001   13.687   3.940     1.906--8.147     \<0.001
                             15--30                   111.663                34.982           18.092--67.639    \<0.001   18.046   6.246     2.682--14.542    \<0.001
                              \<15                    118.059                46.326           23.192--92.536    \<0.001   23.710   9.675     3.881--24.120    \<0.001
                        WHO grade I--III               Ref.                   Ref.                 Ref.                    Ref.     Ref.         Ref.        
                               IV                     83.574                  4.433            3.222--6.101     \<0.001   7.818    1.847     1.201--2.840      0.005
                               V                      231.786                11.790            8.581--16.197    \<0.001   38.291   4.625     2.847--7.511     \<0.001
                         SBP ≥140 mmHg                62.387                  2.543            2.017--3.206     \<0.001   7.136    1.578     1.129--2.206      0.008

Multivariate time-dependent cox regression analysis for patient-death was included age, sex, clinical manifestations of edema/gross hematuria, co-morbidities of hypertension/cancer, BMI, GFR, anemia, albumin \<3.5g/dL, SBP ≥140 mmHg, DBP ≥90 mmHg, proteinuria ≥1 g/day, and pathologic change of global sclerosis, presence of crescent, interstitial inflammation and tubular atrophy/interstitial fibrosis. Sex and global sclerosis did not meet proportional hazards assumption for Cox model. Global sclerosis interacted with GFR and interstitial inflammatory cell infiltration. BMI interacted with age. Therefore such interactions were considered in this model.

Multivariate time-dependent cox regression analysis for renal-death was included age, sex, clinical manifestations of edema/gross hematuria, co-morbidities of diabetes/hypertension/cancer, GFR, anemia, albumin \<3.5g/dL, SBP ≥140 mmHg, DBP ≥90 mmHg, proteinuria ≥1 g/day, pathologic change of segmental sclerosis, and treatment history with statin and renin-angiotensin system blockades. Sex and age were considered changes of proportional hazard according to time progression. Global sclerosis and other tubulointerstial changes were excluded in the final model because of severe interaction with GFR.

Abbreviations: SBP, systolic blood pressure; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; HR, Hazard ratio; CI, confidence interval.

Statistical analysis {#s2e}
--------------------

The data are presented as frequencies and percentages for categorical variables. Continuous variables with normal distribution are indicated as mean ± SD, while those without normal distribution are shown as median and interquartile range (IQR). Comparisons between the outcome group and other groups were performed using the χ^2^ test for dichotomous variables, Student *t*-test for parametric continuous variables, and Mann-Whitney test for non-parametric continuous variables.

10.1371/journal.pone.0051225.t004

###### Causes of death.

![](pone.0051225.t004){#pone-0051225-t004-4}

  Causes of death (N)           Death before ESRD (n = 39)   Death after ESRD (n = 31)   Total
  ---------------------------- ---------------------------- --------------------------- -------
  Renal disease                             2                           11                13
  Cardiovascular disease                    5                            5                10
  Cancer                                    12                           1                13
  Infection                                 6                            4                10
  Traffic accident or injury                3                            1                 4
  Miscellaneous                             2                            3                 5
  Unknown                                   9                            6                15

Abbreviations: ESRD, end-stage renal diseas.

Survival rates for ESRD, death, and composite outcome were analyzed using the Kaplan-Meier method. Survival differences were tested by the log-rank procedure. Cox proportional hazards models were used for prognostic factor assessment. Proportional hazards assumption for Cox models were tested by using log-minus-log plots. Variables that failed to satisfy the proportional hazards assumptions were analyzed by using time-dependent Cox regression analysis. Variables that showed a significant association (*P*\<0.10) in the univariate analysis or that were of considerable theoretical relevance were retained as potential predictors in the multivariate model. In the forward conditional multivariate models, the orders of variable selection and the values of Wald statistics helped to determine the rankings of the risk factors.

![Cumulative patient survival after ESRD progression according to the all ESRD patients\
(**A**) **and excluding transplantation recipients** (**B**)**.** The primary outcome is patient survival. The numbers of patients remaining at 60, 120, 180, 240, 300, and 360 months of follow-up are shown at the bottom. ESRD, end stage renal disease.](pone.0051225.g003){#pone-0051225-g003}

From the results of Cox-regression analyses, we identified 3 major risk factors: SBP ≥140 mmHg, proteinuria ≥1 g/day, and baseline renal insufficiency with eGFR \<60 ml/min per 1.73m^2^. These major risk factors were simplified as a sum of present risk factors as follows: low-risk group for none or one of the risk factors; intermediate-risk group for any 2 of the risk factors, and high-risk group for all their simultaneous presence. Patient survival and renal survival analyses were also performed according to the risk stratification.

10.1371/journal.pone.0051225.t005

###### Causes of death according to use of immunosuppressive agents.

![](pone.0051225.t005){#pone-0051225-t005-5}

                              Steroid IV         Steroid PO      Cyclophosphamide    Calcineurin inhibitor   Mycophenolate
  ------------------------ ----------------- ------------------ ------------------- ----------------------- ---------------
  No of prescription              25                130                 36                     9                   9
  Cumulative dose           1187(450--2437)   3115(1519--4308)   6487(4087--10050)           1833               107000
  Duration                    3(1.8--6.0)       122(75--168)        80(48--123)               107                 111
  No of death                      3                 12                  6                     2                   1
  Cause of death                                                                                            
  Renal disease                    0                 0                   1                     0                   0
  Cardiovascular disease           0                 1                   1                     0                   0
  Cancer                           0                 2                   0                     0                   0
  Infection                        2                 5                   2                     2                   1
  Unknown                          1                 4                   2                     0                   0

Abbreviations: IV, intravenous; PO per oral;

To clarify the mortality rate associated with IgAN, the standardized mortality ratio (SMR) was calculated as the ratio between the observed and the expected number of deaths. The expected number of deaths was calculated by person-year methods as follows: (1) The sum of annual observed person-years was calculated during the observation period (1992--2008). (2) The expected number of deaths was calculated by multiplying the sum of annual observed person-years by sex-adjusted national mortality data in 5-year calendar periods and 5-year age groups. (3) The sum of annual expected number of deaths was calculated. Information about the annual mortality rates of the general Korean population was collected from the KNSO. Because national mortality statistics were available from 1992, SMR was calculated in the patients who had a renal biopsy after 1992. An SMR \>1.0 was considered to be an excess mortality. To calculate the 95% confidence intervals (CIs) for the SMR of each group, the Poisson-distributed number of observed cases was assumed [@pone.0051225-Ulm1]. Two-sided *P* values are reported, with the level of statistical significance set at 0.05. The SPSS Statistics (version 19.0, Chicago, IL, USA) package was used for statistical analysis.

10.1371/journal.pone.0051225.t006

###### Standardized mortality ratios (SMRs) in overall and subpopulation of IgAN patients.

![](pone.0051225.t006){#pone-0051225-t006-6}

                              N     Initial age   Final age   Person-year   Observed   Expected     SMR(95% CI)
  ------------- ----------- ------ ------------- ----------- ------------- ---------- ---------- ------------------
  **Overall**                1009    36.8±13.7    45.0±14.0     8134.2         44        30.7     1.43(1.04--1.92)
  eGFR              ≥60      606     32.9±12.2    41.3±13.2     5077.4         15        13.8     1.08(0.61--1.79)
                   \<60      374     43.4±13.6    50.9±13.2     2825.6         28        16.5     1.70(1.13--2.46)
  Proteinuria    \<1 g/day   341     33.8±13.1    41.0±13.3     2445.5         6         6.2      0.97(0.36--2.12)
                 ≥1 g/day    572     39.1±13.7    47.7±13.7     4941.5         36        21.7     1.66(1.16--2.29)
  SBP              \<140     768     35.2±13.1    42.8±13.4     5911.3         18        18.3     0.98(0.58--1.56)
                   ≥140      230     42.2±14.1    51.4±13.9     2125.2         23        12.3     1.88(1.19--2.82)
  **Men**                    495     36.1±14.7    45.0±15.0     4403.6         29        23.8     1.22(0.82--1.75)
  eGFR              ≥60      309     31.6±12.9    40.7±13.6     2827.9         10        10.2     0.98(0.47--1.81)
                   \<60      173     44.6±14.0    53.1±13.5     1482.8         18        13.4     1.34(0.80--2.13)
  Proteinuria    \<1 g/day   143     31.5±13.7    40.1±14.0     1225.5         3         1.9      1.57(0.32--4.58)
                 ≥1 g/day    307     38.7±14.4    47.8±14.3     2791.7         12        4.6      2.60(1.35--4.55)
  SBP              \<140     356     34.4±14.3    43.0±14.5     3092.0         12        14.1     0.85(0.44--1.49)
                   ≥140      135     40.6±14.9    50.2±14.6     1299.1         15        9.7      1.55(0.87--2.56)
  **Women**                  514     37.5±12.6    45.0±13.0     3730.6         15        6.9      2.17(1.21--3.57)
  eGFR              ≥60      297     34.4±11.3    41.9±12.7     2249.5         5         3.7      1.36(0.44--3.18)
                   \<60      201     42.4±13.2    49.0±12.8     1342.8         10        3.1      3.24(1.55--5.95)
  Proteinuria    \<1 g/day   198     35.5±12.4    41.6±2.9      1220.0         3         4.2      0.71(0.15--2.07)
                 ≥1 g/day    265     39.4±12.7    47.5±13.0     2149.8         24        17.1     1.40(0.90--2.08)
  SBP              \<140     412     35.9±12.0    42.7±12.4     2819.3         6         4.2      1.43(0.53--3.12)
                   ≥140       95     44.5±12.5    53.1±12.7      826.1         8         2.6      3.09(1.34--6.10)

Abbreviations: SMR, standardized mortality ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.

Results {#s3}
=======

Baseline characteristics according to outcome development {#s3a}
---------------------------------------------------------

Overall, 1,364 patients were included in the final analysis. Initial demographic and clinical data are listed in [Table 1](#pone-0051225-t001){ref-type="table"}. The median age at the time of biopsy was 33 years (IQR, 25--45). The proportion of men and women was equal, although age distribution according to sex was quite different. Median age was lower in men (31 years; IQR, 22--45) than in women (35 years; IQR, 27--45). Gross hematuria was present in 33.2% of patients. The mean eGFR was 67.6 ml/min per 1.73m^2^ and proteinuria was 1.3 g/day. In all, 137 patients were treated with immunosuppressive agents, of which 25 were treated with intravenous steroids; 130 with oral steroids; 36 with oral cyclophosphamide; 9 with cyclosporine; and 9 with mycophenolate mofetil.

![Standardized mortality ratio\
(**SMR**) **according to risk stratification.** The x-axis represents SMR with 95% confidence interval in log scale. The y-axis represents overall and gender subgroup of IgAN patients.](pone.0051225.g004){#pone-0051225-g004}

The patients who died were significantly older, and had higher blood pressure, more nephrotic features and more depressed renal function at the time of biopsy than did the survivors. A higher proportion of the patients who died was managed with immunosuppressive agents before death. Patients with ESRD progression were slightly older and included a higher proportion of men than did the non-ESRD group. Nephrotic features, higher blood pressure, lower hemoglobin level and initial renal dysfunction were significantly higher in patients with renal progression. [Table 2](#pone-0051225-t002){ref-type="table"} summarizes the pathological data of the study population. The pathological changes were more severe in both glomerular and tubulointerstitial areas in ESRD patients and in those who died.

[Figure 1](#pone-0051225-g001){ref-type="fig"} compares the overall renal and patient survival rates. In cases of renal survival, 277 (20.6%) patients advanced to renal death. Ten, 20- and 30-year renal survival rates were 82.0%, 70.8% and 67.3%, respectively during a median observation period of 96 (IQR, 56--187) months with 14,495 person-years. The median time to ESRD was 71 (IQR, 32--123) months. Seventy-one (5.3%) patients died during the median observation period of 100 (IQR, 51--210) months, with 13,916 person-years. The median time to death was 101 (IQR, 38--189) months. Ten, 20-, and 30-year patient survival rates were 96.3%, 91.8%, and 82.7%, respectively. For composite outcome, the median observation period was 96 months (IQR, 57--188), with 14,588 person-years. The median time to event was 69 (IQR, 31--165) months. Three-hundred and sixteen (23.2%) patients reached the composite outcome during the long-term follow-up. Ten, 20-, and 30-year patient survival rates were 79.8%, 66.9%, and 62.5%, respectively.

Comparisons of predictors according to renal and patient outcome {#s3b}
----------------------------------------------------------------

Risk factor assessment was performed according to ESRD, death, and composite outcome, respectively, In the univariate analysis, renal survival was predominantly affected gradually by eGFR stage in the univariate analysis, even from an eGFR \<90 ml/min per 1.73m^2^. SBP ≥140 mmHg, proteinuria ≥1 g/day, hypoalbuminemia and edema were the next important determinants of ESRD progression. For death, age was a predominant risk factor even from the age of 40 years. Combined malignancy; SBP ≥140 mmHg; eGFR \<60 ml/min per 1.73m^2^; nephrotic features such as edema, proteinuria, and hypoalbuminemia; and anemia were the next significant predictors of patient death. None of the medical treatment had any demonstrable effect on mortality. In addition, patient survival was influenced by glomerular changes such as global sclerosis, segmental sclerosis, and the presence of any crescent formation. Severe degrees of tubulointerstitial changes were also associated with poor patient survival. For composite outcome, the significant predictors were similar to those of ESRD.

The results of the multivariate analysis for the indicators of ESRD and patient death are summarized in [Table 3](#pone-0051225-t003){ref-type="table"}. In the case of renal survival, initial renal function was the most important determinant, followed, as expected, by hypertension. Segmental sclerosis and hypoalbuminemia remained as significant predictors of renal progression. Gross hematuria was associated with a favorable renal outcome. For patient outcome, advanced age, SBP ≥140 mmHg, hypoalbuminemia and combined malignancy were identified as independent determinants. Interestingly, predictors of patient and renal death appeared to be similar, with hypoalbuminemia and hypertension (or SBP ≥140 mmHg) being common risk factors for both outcomes. Moreover, determinants of the composite outcome seemed to be the combination of the predictors of mortality and ESRD progression. When the simplified risk stratification was applied, it predicted both renal and patient outcome in IgAN patients well ([Figure 2](#pone-0051225-g002){ref-type="fig"}).

Subgroup analysis for patient death {#s3c}
-----------------------------------

Among the 71 deaths, 39(55.7%) patients died before ESRD progression. These 39 patients were significantly older (median age 49 \[IQR, 38--64\] vs.61 \[IQR, 53--68\] years, *P* = 0.049) and showed relatively conserved renal function (median eGFR 55.8 \[IQR, 39.1--71.5\] vs. 37.0 \[IQR, 18.3--53.7\] ml/min per 1.73m^2^, *P* = 0.004) compared to the rest. However, other clinical factors were not different between the 2 groups). [Table 4](#pone-0051225-t004){ref-type="table"} summarizes the causes of death. The causes of death in the patients who died before advancing to ESRD progression were malignancies (12 patients, 30.8%), cardiovascular diseases (5 patients, 12.8%), and infection (6 patients, 15.8%). Death from ESRD and dialysis-related complications occurred in only 2 patients. In contrast, the deaths after ESRD progression were caused by renal disease (11 patients, 35.5%), and cardiovascular disease (5 patients, 16.1%), with only one case of cancer mortality.

As expected, ESRD progression was a significant predictor of mortality (hazard ratio, 2.593; 95% CI, 1.609--4.177; *P* \<0.001). After ESRD progression, 25.3% patients received renal transplantation. Among the patients who received transplantation, only 3 patients died, 1 from infection and the other 2 after allograft failure and resumption of dialysis. All of them were dead by 12 years after ESRD progression. As a result, although the 10-year survival rate after ESRD was higher in all ESRD patients including transplantation recipients, than in those excluding transplantation recipients, the 20-year survival rate of ESRD was similar in both groups at about 65% ([Figure 3](#pone-0051225-g003){ref-type="fig"}).

Thirteen patients who were managed by immunosuppressive agents had died. Among them, 5 patients died from infection and two patients died from malignancy. Three patients whose cause of death was infection had underlying cancer ([Table 5](#pone-0051225-t005){ref-type="table"}). There was no relationship between the cumulative dose of immunosuppressive agents and any death or infection-associated death (data was not shown).

Standardized mortality ratio in IgAN {#s3d}
------------------------------------

[Table 6](#pone-0051225-t006){ref-type="table"} summarizes the overall and sex-specific SMR results. The overall relative mortality rate of IgAN patients was significantly higher by 43% than that of age/sex-matched GP (SMR, 1.43; 95% CI, 1.04--1.92). Interestingly, the mortality rate was different according to subgroups. An excess mortality rate was found in women (SMR, 2.17; 95% CI, 1.21--3.57), but not in men (SMR, 1.22; 95% CI, 0.82--1.75) with IgAN. Moreover, patients with lower eGFR (\<60 ml/min per1.73m^2^; SMR, 1.70; 95% CI, 1.13--2.46), higher proteinuria (≥1 g/day; SMR, 1.66; 95% CI, 1.16--2.29), or higher SBP (≥140 mmHg; SMR, 1.88; 95% CI, 1.19--2.82) had an elevated mortality rate compared with their age/sex-matched GP, whereas patients without such risk factors had a similar mortality rate.

When the SMR was further classified by the simplified risk stratification, IgAN patients in the low-risk group had a similar mortality rate to the GP. In the intermediate-risk group, IgAN patients' mortality appeared higher than that in the GP, although insignificant. However, in the high-risk group, IgAN patients' mortality was significantly higher than that in the GP. Interestingly, this relationship was different according to sex. Thus, risk stratification did not have any influence on the SMR in men, but SMR in women was affected significantly ([Figure 4](#pone-0051225-g004){ref-type="fig"}).

Discussion {#s4}
==========

Until recently, investigations on IgAN have focused on renal prognosis because it is the most common primary glomerulonephritis and a significant contributor to the development of ESRD, despite the slow rate of progression [@pone.0051225-Donadio1], [@pone.0051225-DAmico1]. However, there has been no information about death, which is more definitive outcome than ESRD. In this investigation, we demonstrated that the 30-year mortality of IgAN patients was 82.7%. Moreover, we showed that mortality of IgAN patients was higher than that of the age/sex-matched GP by 43%. To the best of our knowledge, this is the first study to investigate patient survival and its predictive factors as distinguished from renal survival in IgAN patients.

The most notable finding in our survival analyses is that although the overall relative mortality of IgAN, expressed by SMR, was shown to be higher than that of the GP, the absolute mortality rate was not very high when considering the significant renal progression to ESRD. More than half of the deaths occurred even before ESRD progression and the most common cause of death was malignancy. In particular, the patients who survived and progressed to ESRD had a better survival rate than the general dialysis patients did. According to the Korean ESRD registry, the 10-year survival rate of the overall dialysis patients was about 45%, and the 10-year survival rate of the non-diabetic dialysis patients within this group was 58.5% [@pone.0051225-Jin1]. In the 2011 US Renal Data System data, survival over the first 5 years of therapy was only 45% in the patients with glomerulonephritis [@pone.0051225-Collins1]. Compared with the above data, the ESRD patients with IgAN in this investigation have a favorable survival rate. The relatively young age of the ESRD population in this study may have explained the favorable survival. In this study, the mean age of the 277 patients who progressed to ESRD was 45 years, which was lower than the mean age (52.1 years) of the 5,550 glomerulonephritis-induced ESRD patients in the Korean ESRD registry [@pone.0051225-Jin1]. With regard to transplantation, this may have contributed to the improved survival in the ESRD patients with IgAN for 10-year survival rate, but not the 20-year survival rate. To clarify the precise mechanisms of the fair survival rate for IgAN patients with ESRD, further well-designed investigations are needed.

Interestingly, the survival patterns differed according to the sex, renal function, proteinuria and blood pressure. Patients who were male, with preserved renal function, normotension, and proteinuria \<1 g/day had a similar mortality rate compared with the GP, whereas female patients, or patients with renal dysfunction, higher blood pressure and proteinuria ≥1 g/day had significantly higher mortality, compared with the GP. The results for the 3 subgroups (renal dysfunction, higher blood pressure, and proteinuria ≥1 g/day) were similar, although the difference according to sex was unexpected result. In the regression analysis, a sex difference was not detected even in the univariate analysis. However, men showed a comparable survival rate, whereas women tended to have a higher mortality rate compared with the age-matched Korean GP, although the actual number of patients who died was higher in men. On average, men had a 20% higher death rate than did women. The difference was increased up to 3-fold in their 40s and 50s compared with Korean GP (<http://kostat.go.kr>). This difference may cause the discordance between the relative and absolute mortality in IgAN patients. The precise mechanisms of the sex difference in relative mortality remain to be defined.

The survival pattern of IgAN patients described in this analysis suggests the need for some changes in clinical practice. Despite the high prevalence of IgAN, adequate and specific treatment intervention in the early stage of IgAN remains controversial. Therefore, both clinicians and patients tend to hesitate before following an active therapeutic approach to individual IgAN patients, even at high risk for progression. However, the decreased age at diagnosis, reduced cardiovascular risk factors and increased average life expectancies have allowed more IgAN patients to live with ESRD state for a relatively longer duration, compared with other causes of ESRD including diabetes. ESRD treatment clearly presents a considerable burden to both society and the patients [@pone.0051225-Collins1]. The cost per person-year of ESRD was the highest and that of transplantation was the fourth highest among the 500 common disease categories in Korea. Moreover, expenditure per person-year for ESRD has increased continuously up to US\$12,639 per patient per year in 2010 (<http://www.nhic.or.kr>). Thus, the fair survival rate of IgAN patients also implies a substantial social cost for ESRD. Therefore, optimal treatment guidelines, including both active and supportive care need to be developed for IgAN patients according to their renal risk stratification in order to reduce renal progression.

While the present study suggested some novel findings, there are several limitations. First, this investigation was a retrospective observational study in a single center. During the long follow-up period, the general medical status and/or treatment strategy of the patients changed over time. However, we could not reflect such changes, and only took initial medical treatments into account. For this reason, the incompleteness of the data and the possibility of residual confounding cannot be excluded. For example, information about patients who received tonsillectomy was not available in our analyses. A validation study in an external cohort or a prospective multicenter study may be necessary to overcome our study limitations. The inability to elucidate reproducibility in pathological diagnosis is another weak point of our investigation.

In conclusion, we have demonstrated that the absolute 30-year survival of IgAN was 82.7%. Moreover, the relative mortality was higher than that of the age/sex-matched GP by 43%. Especially, relative mortality was higher in a subgroup with well-known renal risk factors and in women. However, patients without renal risk factors survived similarly to the GP. Considering the socioeconomic burdens of ESRD, more meticulous and active management to mitigate renal progression is warranted in IgAN patients.
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